OrbiMed Advisors LLC's Form 4 filing
Theseus Pharmaceuticals, Inc. (THRX) · filed Jul 19, 2023
- Accession no.
- 0000947871-23-000760
- Filed
- Jul 19, 2023, 4:15 PM ET
- Trade date
- Jul 17, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $1.46M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | Director, 10% Owner |
| OrbiMed Capital GP VII LLCCIK 0001760648 | Director, 10% Owner |
| OrbiMed Genesis GP LLCCIK 0001808744 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average purchase price of the shares of the Issuer's common stock ("Shares") purchased, ranging from a low of $3.04 to a high of $3.05 per Share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Shares purchased at each separate price.
Referenced by the price of 2 transactions in Table I.